QTORIN™ Technology

PTX-022 (novel, high-strength rapamycin topical formulation, optimized for dermal targeting) leverages Palvella’s proprietary QTORIN™ technology to overcome inherent stability, skin penetration, and skin distribution challenges posed by mTOR inhibitors such as rapamycin. QTORIN™ utilizes a highly specific composition of excipients precisely selected to achieve drug stability at room temperature and enable cutaneous distribution into the stratum basale of the epidermis and the reticular dermis where the disease pathology manifests.